Merck & Co. is officially on its way to eclipsing BMS in lung cancer. Its immuno-oncology drug Keytruda won a breakthrough tag for first-line treatment, a…

Novo Nordisk’s combination diabetes drug didn’t lap Sanofi’s after all. Two weeks after the FDA put off approval of the French drugmaker’s insulin-plus-GLP-1…

The U.K.’s promotional police cracked down on biosimilar marketing this week, citing Pfizer’s Hospira unit and Napp Pharmaceuticals for code violations at…

After a former Insys Therapeutics sales rep admitted she had paid kickbacks to doctors to prescribe the company's sprayed cancer pain opioid fentanyl for…

Valeant just got a new weapon in its battle with AstraZeneca for the opioid-induced constipation throne. But don't expect oral Relistor to power that…

AstraZeneca may so far be on the outside looking in with its DPP-4/SGLT2 combo when it comes to the U.S. market. On its home continent, though, it now has a…

Golf outings at top courses. Box suites at sporting events. A Los Angeles Lakers basketball camp. And the usual “lavish dinners.” They all figured into a $30…

An offhand Novartis disclosure Tuesday showed that Amgen scored a break on biosimilars: The FDA rejected Novartis' biosim version of the Big Biotech'…

Pfizer and the city of Chicago have hammered out an agreement on painkiller marketing, setting out a code of conduct to help ensure the powerful drugs are…

Regulatory